Cohance Lifesciences Limited (NSE:COHANCE)
India · Delayed Price · Currency is INR | Market Cap | 180.76B -31.6% |
| Revenue (ttm) | 20.57B +70.0% |
| Net Income | 473.70M -73.2% |
| EPS | 1.23 -82.1% |
| Shares Out | 382.60M |
| PE Ratio | 384.31 |
| Forward PE | 68.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 502,566 |
| Open | 463.30 |
| Previous Close | 464.10 |
| Day's Range | 457.30 - 474.00 |
| 52-Week Range | 266.70 - 697.50 |
| Beta | 0.59 |
| Analysts | Hold |
| Price Target | 508.00 (+7.53%) |
| Earnings Date | Nov 6, 2026 |
About Cohance Lifesciences
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores... [Read more]
Financial Performance
In fiscal year 2026, Cohance Lifesciences's revenue was 22.69 billion, a decrease of -13.03% compared to the previous year's 26.09 billion. Earnings were 1.79 billion, a decrease of -63.22%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for COHANCE stock is "Hold." The 12-month stock price target is ₹508.00, which is an increase of 7.53% from the latest price.
News
Cohance Lifesciences Transcript: Q2 26/27
Q2 revenue and adjusted EBITDA recovered sequentially, and management expects H2 YoY growth. Destocking, Specialty Chemicals weakness, regulatory uncertainty, and the Suryapet closure order remain key constraints.
Cohance Lifesciences Quarterly report: Q2 2027
Cohance Lifesciences has published its Q2 2027 quarterly earnings report on November 6, 2026.
Cohance Lifesciences Slides: Q2 2027
Cohance Lifesciences has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 6, 2026.
Cohance Lifesciences Transcript: Q1 26/27
Q1 FY 2027 saw a 23% revenue decline due to shipment phasing and lower contributions from key segments, but sequential improvement and year-on-year growth are expected from H2, driven by restocking, new product launches, and strong performance in API Plus and Sapala. Margin recovery is anticipated in the second half, with capital allocation focused on innovation-led opportunities.
Cohance Lifesciences Quarterly report: Q1 2027
Cohance Lifesciences has published its Q1 2027 quarterly earnings report on August 5, 2026.
Cohance Lifesciences Slides: Q1 2027
Cohance Lifesciences has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 5, 2026.
Cohance Lifesciences Transcript: Q4 25/26
FY 2026 saw a 13% revenue decline due to destocking, shipment delays, and site disruptions, but gross margins remained strong at 70.8%. Growth is expected to return in H2 FY 2027, driven by new product launches, improved utilization, and a diversified pipeline.
Cohance Lifesciences Quarterly report: Q4 2026
Cohance Lifesciences has published its Q4 2026 quarterly earnings report on May 12, 2026.
Cohance Lifesciences Slides: Q4 2026
Cohance Lifesciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 12, 2026.
Cohance Lifesciences Annual report: Q4 2026
Cohance Lifesciences has published its Q4 2026 annual report on May 12, 2026.
Cohance Lifesciences Transcript: Q3 25/26
FY 2026 saw a 6.7% revenue decline and 40% drop in adjusted EBITDA, driven by customer inventory normalization, regulatory issues, and product mix. Management expects growth to resume in FY 2027, with a robust pipeline and continued investment in technology and quality systems.
Cohance Lifesciences Quarterly report: Q3 2026
Cohance Lifesciences has published its Q3 2026 quarterly earnings report on February 12, 2026.
Cohance Lifesciences Slides: Q3 2026
Cohance Lifesciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 12, 2026.
Cohance Lifesciences Transcript: Q2 25/26
Revenue declined 8% year-on-year in Q2 FY2026 due to shipment deferrals, but material margins improved and adjusted for restocking, growth was 14%. FY2026 revenue is expected to be flat versus FY2025, with H2 anticipated to be stronger. Biotech funding headwinds and plant issues remain key risks.
Cohance Lifesciences Quarterly report: Q2 2026
Cohance Lifesciences has published its Q2 2026 quarterly earnings report on November 12, 2025.
Cohance Lifesciences Slides: Q2 2026
Cohance Lifesciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 12, 2025.